Aprea Therapeutics Q3 net loss widens on higher R&D spending
APRE•APRE•APRE•APRE•Aprea Therapeutics’ third-quarter net loss widened to $4.8 million, and its operating loss increased to $5.2 million as research and development spending rose. Cash and equivalents were $37.8 million, with the company expecting its runway to extend into the first quarter of 2028.
Aprea Therapeutics reported a third-quarter net loss of $4.8 million and an operating loss of $5.2 million. The company said higher research and development expenses were mainly due to increased spending on ACESOT-1051, its Phase 1 study of lead candidate APR-1051.
Cash and equivalents stood at $37.8 million, and the company expects its cash runway to extend into the first quarter of 2028 based on its current operating plan. Aprea plans to select a dose for Part 2 of the APR-1051 study in the first half of 2027 and expects increased R&D expenses as the trial expands to nine sites.
